Absci Reports Positive Interim Phase 1 Data for ABS-201
Absci reported positive interim Phase 1 data for its ABS-201 antibody, highlighting a favorable safety profile and long half-life. This early-stage data lays the groundwork for advancing its hair loss and endometriosis treatments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day